Eli Lilly (LLY) and Novo Nordisk (NVO) to dominate as TD Cowen lifts 2030 sales forecast for GLP-1 class of obesity/ diabetes ...

In a sense, every investor is a growth investor. Even those who are primarily seeking income enjoy when the stocks they buy ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $732 billion, has been making waves in the biopharmaceutical industry with its strong portfolio of ...

We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra Investments. In this article, we will ...

Eli Lilly has been a terrific stock to own for the past five years, thanks to its excellent clinical and regulatory progress.

The upgrade is based on Moody's expectation of robust earnings growth for Eli Lilly in the coming years. This growth is ...

These pipeline assets, if successful, could not only drive revenue growth but also diversify Eli Lilly's portfolio, reducing reliance on its current blockbuster products and providing multiple ...

Eli Lilly's product portfolio is anchored by its GLP ... rising by 21.6% week-over-week to 473,533 in a recent report. The company's pipeline is also generating excitement among analysts.

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company has taken the GLP-1 supply chain too far.

The big pharma sector is one that’s generally fallen out of favor for many investors over the past few decades, as large ...

Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...

The information we provide about our products and pipeline is ... 2024 was a productive year for Lilly. We grew our top line, advanced our pipeline, and invested in our supply chain to meet ...